Revision of Precautions

Panitumumab

March 24, 2015

Non-proprietary name
Panitumumab (genetical recombination)

Safety measure
Precautions should be revised in the package insert.

In the Clinically significant adverse reactions subsection of the Adverse reactions section, the following texts should be added (underlined parts are revised):

Oculomucocutaneous syndrome (Stevens–Johnson syndrome):
Oculomucocutaneous syndrome may occur. Patients should be carefully monitored. If any abnormalities are observed, administration of this drug should be discontinued and appropriate measures should be taken.

NOTE
- This drug is designated to prepare a Drug Guide for Patients.